Related Experiment Video

Updated: Jul 3, 2026

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

Hyeon Cheol Cho1, Bo Hwan Kim, Kyunghoon Kim

  • 1Department of Microbiology, Wonju College of Medicine, Yonsei University, Wonju 220-701, South Korea.

International Immunopharmacology
|August 9, 2008
PubMed

Insights

A novel CpG oligodeoxynucleotide (ODN), KSK-CpG, effectively boosts anti-tumor immunity. This cancer immunotherapeutic prolongs survival and reduces tumor nodules by enhancing natural killer (NK) and cytotoxic T lymphocyte (CTL) responses.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • CpG oligodeoxynucleotides (ODN) show promise as cancer immunotherapeutics.
  • Limited availability of clinically usable CpG ODNs hinders their application.
  • Novel CpG ODN development is crucial for advancing cancer immunotherapy.

Purpose of the Study:

  • To evaluate the efficacy of a novel CpG ODN, KSK-CpG, as a cancer immunotherapeutic.
  • To assess KSK-CpG's impact on in vivo and in vitro anti-tumor parameters.
  • To investigate KSK-CpG's effects on immune cell activity and cytokine release.

Main Methods:

  • Utilized a murine tumor model (B16BL6 and EL4).
  • Administered novel CpG ODN (KSK-CpG) to tumor-bearing mice.
  • Monitored survival span, tumor nodule count, natural killer (NK) cell activity, cytotoxic T lymphocyte (CTL) activity, and cytokine (IL-6, IL-12) release from splenocytes.

Main Results:

  • KSK-CpG significantly prolonged survival span in the murine cancer model.
  • Reduced the number of tumor nodules in treated mice.
  • Augmented NK cell and CTL cytotoxicity.
  • Evoked increased release of IL-6 and IL-12 cytokines from splenocytes.

Conclusions:

  • KSK-CpG demonstrates significant anti-tumor activity in a murine model.
  • The efficacy of KSK-CpG is mediated through innate immune augmentation.
  • KSK-CpG represents a promising novel candidate for cancer immunotherapy.

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...